Compare NBY & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBY | PPBT |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 398.2M | 45.3M |
| IPO Year | 2007 | 2014 |
| Metric | NBY | PPBT |
|---|---|---|
| Price | $1.19 | $4.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 80.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.42 | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $370,000.00 | N/A |
| Revenue This Year | $23.91 | N/A |
| Revenue Next Year | $32.05 | N/A |
| P/E Ratio | $1.82 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $0.41 |
| 52 Week High | $19.95 | $5.18 |
| Indicator | NBY | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 41.33 | 84.60 |
| Support Level | $0.99 | $0.57 |
| Resistance Level | $1.36 | N/A |
| Average True Range (ATR) | 0.26 | 0.25 |
| MACD | 0.21 | 0.45 |
| Stochastic Oscillator | 31.95 | 86.58 |
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.